文献速递血栓与止血

儿童急性静脉血栓栓塞延长抗凝治疗:EINSTEIN-Jr 3期试验队列研究

Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.
PubMed 文献 · Lancet Haematol · 2025-04-10

本研究基于EINSTEIN-Jr试验中完成3个月急性期抗凝的儿童,评估延长抗凝的疗效与安全性并分析延长决策相关因素。248例(51%)接受延长抗凝,其中研究内214例,复发静脉血栓栓塞累积发生率3.0%,临床相关非大出血3.3%,无致死性静脉血栓栓塞或大出血。症状性索引事件、无诱因或持续危险因素及残留血栓与延长抗凝决策相关。

要点

  • 延长抗凝期间复发静脉血栓栓塞累积发生率3.0%(95%CI 0.9-9.8),临床相关非大出血3.3%(95%CI 1.2-9.2)。
  • 未发生致死性静脉血栓栓塞或大出血,利伐沙班与标准抗凝结局发生率相似。
  • 症状性索引事件、无诱因或持续危险因素及残留血栓与延长抗凝决策相关。

核心结论

  • 延长抗凝期间复发静脉血栓栓塞和出血发生率低,与急性期治疗及成人延长抗凝研究相似,为儿童延长抗凝临床实践提供有价值信息。

研究设计与样本

  • EINSTEIN-Jr(NCT02234843)3期随机对照试验的队列研究,纳入28个国家107家儿科医院中完成3个月急性抗凝(小于2岁导管相关静脉血栓栓塞为1个月)的17岁及以下儿童。
  • 完成急性期后儿童可延长研究治疗至9个月(小于2岁导管相关静脉血栓栓塞至2个月),抗凝药为体重调整利伐沙班(片剂或混悬液,20 mg等效剂量)或标准抗凝药(肝素或维生素K拮抗剂)。
  • 主要结局为疑似复发静脉血栓栓塞(主要疗效结局)和临床相关出血(主要安全性结局),均经客观检查确认或排除。

主要发现

  • 2014年11月14日至2019年1月15日,248例(51%)儿童接受延长抗凝,其中214例在研究框架内,34例在研究框架外。
  • 研究内214例中,延长抗凝期间复发静脉血栓栓塞3例(1%),累积发生率3.0%(95%CI 0.9-9.8)。
  • 研究内214例中,临床相关非大出血4例(2%),累积发生率3.3%(95%CI 1.2-9.2);未发生致死性静脉血栓栓塞或大出血。
  • 利伐沙班与标准抗凝的结局发生率相似。
  • 症状性索引静脉血栓栓塞(OR 1.88;95%CI 1.14-3.11)、无诱因静脉血栓栓塞或持续危险因素(OR 2.16;95%CI 1.46-3.19)及复查影像残留血栓(OR 3.79;95%CI 2.52-5.71)与延长抗凝决策相关。

临床怎么用

  • 延长抗凝期间复发静脉血栓栓塞和出血发生率低,与急性期治疗及成人延长抗凝研究相似,为儿童延长抗凝临床实践提供有价值信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended-phase anticoagulation of venous thromboembolism in children is not well documented nor systematically reported. Previously, we reported on recurrent venous thromboembolism and bleeding during acute-phase anticoagulation in EINSTEIN-Jr, a randomised controlled study in 500 children with venous thromboembolism comparing rivaroxaban to standard anticoagulants. The aim of the present study was to evaluate the efficacy and safety of extended-phase anticoagulant therapy in children and to characterise factors associated with the decision to extend anticoagulation. METHODS: Children aged 17 years or younger, who were enrolled in the EINSTEIN-Jr trial (NCT02234843) from 107 paediatric hospitals in 28 countries, and who had previously completed a 3-month acute anticoagulation treatment phase (1-month in children <2 years with catheter-related venous thromboembolism) for acute venous thromboembolism within the trial were included in this cohort study. After completion of the preceding acute anticoagulation treatment phase, children could extend study treatment for up to 9 months (or up to 2 months for children <2 years with catheter-related venous thromboembolism). Study anticoagulants were bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20 mg equivalent dose or standard anticoagulants (heparin or vitamin K antagonist). The main outcomes were suspected recurrent venous thromboembolism (primary efficacy outcome) and clinically relevant bleeding (principal safety outcome), both confirmed or refuted by appropriate objective testing. Cumulative incidences of efficacy and safety outcomes are reported for children who received extended anticoagulation within the framework of the study. We also compared demographic and clinical characteristics of those administered any extended-phase anticoagulation (whether within or outside the framework of the study) with those not administered extended-phase anticoagulation, applying multivariable logistic regression. FINDINGS: 248 (51%) children received extended-phase anticoagulation between Nov 14, 2014, and Jan 15, 2019, 214 within the study and 34 outside the framework of the study. During extended-phase anticoagulant treatment, recurrent venous thromboembolism occurred in three (1%) of the 214 children within the study (cumulative incidence 3·0%; 95% CI 0·9-9·8). Clinically relevant non-major bleeding occurred in four (2%) of 214 children (3·3%; 1·2-9·2). Fatal venous thromboembolism or major bleeding did not occur. Outcome rates were similar with rivaroxaban or standard anticoagulants. Symptomatic index venous thromboembolism (odds ratio 1·88; 95% CI 1·14-3·11), unprovoked venous thromboembolism or persistent risk factor (2·16; 1·46-3·19), and residual thrombosis on repeat imaging (3·79; 2·52-5·71) were associated with the decision to extend anticoagulation. INTERPRETATION: Incidences of recurrent venous thromboembolism and bleeding during extended-phase anticoagulant treatment were low and similar to those observed during acute-phase treatment and adult studies on extended-phase anticoagulant treatment, providing valuable information for clinical practice on extended anticoagulation in children. FUNDING: Bayer and Janssen Research & Development.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Male C, Lensing AWA, Chan AKC, et al. Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. Lancet Haematol. 2025. PMID: 40222370. doi:10.1016/S2352-3026(25)00067-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。